Marine pharmacology in 2005–2006: Antitumour and cytotoxic compounds
- 13 August 2008
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 44 (16), 2357-2387
- https://doi.org/10.1016/j.ejca.2008.07.001
Abstract
No abstract availableThis publication has 170 references indexed in Scilit:
- Marine pharmacology in 2003–4: Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of actionComparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 2007
- Theopapuamide, a Cyclic Depsipeptide from a Papua New Guinea Lithistid Sponge Theonella swinhoeiJournal of Natural Products, 2006
- Inhibition of RecBCD Enzyme by Antineoplastic DNA Alkylating AgentsJournal of Molecular Biology, 2006
- Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent mannerBiochemical and Biophysical Research Communications, 2006
- In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drugInvestigational New Drugs, 2006
- Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancersInvestigational New Drugs, 2005
- Variolin B and its derivate deoxy-variolin B: New marine natural compounds with cyclin-dependent kinase inhibitor activityEuropean Journal Of Cancer, 2005
- Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumorsInvestigational New Drugs, 2005
- Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743European Journal Of Cancer, 2005
- Marine pharmacology in 2001–2: antitumour and cytotoxic compoundsEuropean Journal Of Cancer, 2004